Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

Inclusion Criteria: * Both male and female patients ≥19 years old * Diagnosed with primary glioblastoma by histopathological examination and confirmed recurrent glioblastoma by magnetic resonance imaging (MRI) scans after concomitant temozolomide chemotherapy with radiotherapy (CCRT). One previous recurrence/progression of glioblastoma with reintroduction/altered schedule of temozolomide is allowable. * At least one confirmed measurable lesion or non measurable lesion by response assessment in neuro-oncology (RANO) criteria * Karnofsky Performance Status (KPS) ≥ 80 * A person who satisfies the following criteria in hematologic, renal, and hepatic function tests * At least 12 weeks of expected survival time * Signed informed consent Exclusion Criteria: * Diagnosed with other malignant tumor within 2years * Uncontrolled HT or seizure, class III or IV heart failure, oxygen dependent disease, active psychiatric disorder * Not recovered grade 2 AE due to previous CCRT * Major surgery or other investigational drug treatment within 4 weeks * Pregnant/lactating female and female/male potential childbearing without contraception * Severe drug hypersensitivity or hypersensitivity to a therapy similar to the study drug * Expectation of poor compliance * Previous therapy with VEGF targeted agent